Company: CRAC
Filing Date: 2025-07-11
Form Type: S-1/A
Source: 0001213900-25-063347
Chunk: 21

Company: Crown Reserve Acquisition Corp. I
Filing Date: 2025-07-11
Form: S-1/A
Chunk 21
---
 companies. He serves on the board of Semper Paratus Acquisition Corporation (n/k/a Tevogen Bio Holdings Inc. (NASDAQ: TVGN)) and on the board of a U.S. based nonprofit, Quench and Nourish. Mr. Wadhwani earned a degree in Computer Science and a Masters in Marketing degree, both from the University of Mumbai. He holds an MBA (Executive) from the Columbia Business School in New York City. Mayur Doshi(age: 63) has agreed to serve as a member of our board of directors and to serve as a member of our compensation committee and audit committee. He is a distinguished entrepreneur and leader with over 25 years of experience in the pharmaceutical industry, specializing in Active Pharmaceutical Ingredients (API) and finished dosage form distribution. Mr.Doshi has served as a President of Allied Pharma since 2015. Since 2015, Mr.Doshi has driven strategic initiatives and leveraged his extensive expertise to fuel growth and innovation in pharmaceutical and biotech companies like AlfaGene Bioscience, Inc., where he serves as President and CEO. In addition to his roles at Allied Pharma and AlfaGene Bioscience,Inc., Mr.Doshi has served as a director of TRxADE Health, Inc. (now NASDAQ: SCNX) since May 2024 and is a director of Saptalis Pharmaceuticals. He also joined the board of PWUP in August 2023. Mr.Doshi is an active investor in emerging fields such as stem cell research, immunology, reverse mergers and SPACs. His contributions extend beyond the corporate realm; he is also involved with Shrimad Rajchandra Mission Dharampur (SRMD), a spiritual organization dedicated to inner development and community service. He received a Master’s in Chemical Engineering from Manhattan College. The past performance of our sponsor, directors, officers, and advisors is not a guarantee either (i) of success with respect to any business combination we may consummate or (ii) that we will be able to identify a suitable candidate for our initial business combination. As described in this prospectus, some of our officers and directors have had management experience with blank check companies or special purpose acquisition companies in the past. You should not rely on their respective historical records or performance as indicative of our future performance. Our officers and directors are not prohibited from becoming either a director or officer of any other special purpose acquisition company with a class of securities registered under the Securities Exchange Act of 1934, as amended